“significant promise for the future of vaccine development and global health” says Clinical Trial Vanguard of the Micron, Emory and CDC collaboration on next-generation rotavirus vaccines

June 17, 2025

Clinical Trials Vanguard spotlights news that Emory University and Micron Biomedical have launched the first clinical trial of a rotavirus vaccine, CC24, delivered via dissolvable microarray patch technology, Here’s an excerpt:

“This trial is crucial because it offers a potential solution to a significant global health challenge…Moreover, the trial’s use of needle-free technology could revolutionize vaccine delivery, enhancing accessibility and potentially improving vaccination rates even in developed countries by overcoming needle phobia.

…Furthermore, the validation of this needle-free delivery system could transform how other vaccines and therapeutics are administered, opening up new possibilities for improving healthcare delivery worldwide.